Oddo BHF Asset Management Sas Sells 36,482 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Oddo BHF Asset Management Sas lowered its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 78.2% in the first quarter, Holdings Channel reports. The firm owned 10,151 shares of the pharmaceutical company’s stock after selling 36,482 shares during the quarter. Oddo BHF Asset Management Sas’ holdings in Vertex Pharmaceuticals were worth $4,533,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in VRTX. Motiv8 Investments LLC bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $26,000. Swiss RE Ltd. acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $28,000. Eagle Bay Advisors LLC bought a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at about $29,000. IMG Wealth Management Inc. raised its holdings in Vertex Pharmaceuticals by 277.8% in the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 50 shares during the period. Finally, Ares Financial Consulting LLC bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth approximately $33,000. 90.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on VRTX. Wall Street Zen cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Morgan Stanley upped their price objective on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. UBS Group increased their price objective on shares of Vertex Pharmaceuticals from $545.00 to $585.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Truist Financial lifted their price target on Vertex Pharmaceuticals from $542.00 to $560.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, Canaccord Genuity Group reduced their price objective on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating on the stock in a research note on Tuesday, May 5th. Twenty-two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $559.61.

Insider Activity at Vertex Pharmaceuticals

In other news, EVP Duncan Mckechnie sold 1,541 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total transaction of $799,779.00. Following the transaction, the executive vice president owned 11,001 shares in the company, valued at approximately $5,709,519. This represents a 12.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total transaction of $787,485.00. Following the transaction, the executive vice president directly owned 45,321 shares in the company, valued at $23,793,071.79. This trade represents a 3.20% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 17,770 shares of company stock valued at $8,238,744. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex’s planned $10 billion acquisition of Crinetics Pharmaceuticals would add endocrine assets and broaden its growth pipeline beyond cystic fibrosis. The deal also highlights Vertex’s willingness to use its strong cash-generation profile to pursue new growth opportunities. Vertex Just Paid $10 Billion for Crinetics
• Positive Sentiment: Vertex and AbCellera announced a collaboration to discover, develop, manufacture and commercialize multispecific T-cell engagers for autoimmune diseases and other conditions. Vertex will fund the research and retain commercialization rights, potentially expanding its long-term pipeline into new therapeutic areas. AbCellera, Vertex partner on next-gen T-cell engagers
• Positive Sentiment: Erste Group Bank raised its Vertex EPS forecast to $16.95 for fiscal 2026 and $19.26 for fiscal 2027. The 2027 estimate is above the broader consensus of $17.01 for the current year, indicating improving analyst expectations.
• Neutral Sentiment: Brokerages maintain a consensus “Moderate Buy” rating. However, valuation opinions remain divided: discounted-cash-flow analysis suggests upside, while market-based multiples appear closer to fair value after the shares’ strong longer-term performance. Vertex Receives Moderate Buy Recommendation
• Neutral Sentiment: Investors are also focused on Vertex’s second-quarter 2026 results. Pre-earnings coverage is emphasizing operating metrics and pipeline progress, but no new quarterly results were reported in these articles, leaving near-term direction dependent on the upcoming release.
• Negative Sentiment: The Crinetics acquisition represents a substantial financial commitment and could pressure Vertex’s valuation if integration is difficult, development costs rise or the acquired pipeline fails to produce meaningful revenue. This appears to be the principal source of caution behind the recent weakness.

Vertex Pharmaceuticals Stock Down 0.3%

Shares of VRTX stock opened at $481.70 on Friday. The firm has a 50 day moving average of $469.76 and a 200-day moving average of $460.21. The company has a market cap of $122.26 billion, a price-to-earnings ratio of 28.57, a price-to-earnings-growth ratio of 2.18 and a beta of 0.29. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $533.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. The company had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. Vertex Pharmaceuticals’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.06 EPS. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 17.01 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.